Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

Chronic myeloid leukemia patients display heterogeneous responses to imatinib. Survival depends on baseline clinical characteristics (including prognostic scoring systems) and on early response (such as >10% BCR-ABL/ABL ratio at 3 months of therapy). The results of switching to second-generation...

Descripción completa

Detalles Bibliográficos
Autores principales: Casado, Luis-Felipe, García-Gutiérrez, José-Valentín, Massagué, Isabel, Giraldo, Pilar, Pérez-Encinas, Manuel, de Paz, Raquel, Martínez-López, Joaquín, Bautista, Guiomar, Osorio, Santiago, Requena, María-José, Palomera, Luis, Peñarrubia, María-Jesús, Calle, Carmen, Hernández-Rivas, José-Ángel, Burgaleta, Carmen, Maestro, Begoña, García-Ormeña, Nuria, Steegmann, Juan-Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529338/
https://www.ncbi.nlm.nih.gov/pubmed/25756742
http://dx.doi.org/10.1002/cam4.440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529338/
https://www.ncbi.nlm.nih.gov/pubmed/25756742
http://dx.doi.org/10.1002/cam4.440

Ejemplares similares